Medicare AdvantagePrior AuthMedium impact
Tezruly™ (terazosin) (Revised)
Humana·Urology, Family Medicine, Internal Medicine +1 more·Medicare Advantage
Effective date
May 28, 2025
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Tezruly (terazosin oral solution) for benign prostatic hyperplasia and hypertension. Patients must have tried and failed or been intolerant to at least one generic alpha-1 blocker before approval.
Action Required
By May 28, 2025: Before prescribing Tezruly (terazosin oral solution) for Medicare Advantage patients, providers must obtain prior authorization by documenting diagnosis of BPH or hypertension and previous treatment failure or intolerance to at least one generic alpha-1 blocker (alfuzosin, doxazosin, prazosin, terazosin). For hypertension cases, also document trial of ACE inhibitor, ARB, calcium channel blocker, or diuretic. Update EMR templates to include these requirements.